Beam Therapeutics (BEAM) fell more than 5% in recent trading Tuesday after reporting a wider Q1 loss from the same period a year earlier.
The company reported a Q1 net loss of $1.24 per share, widening from a loss of $1.21 a year earlier.
Analysts polled by FactSet expected a loss of $1.18.
License and collaboration revenue for the quarter ended March 31 was $7.5 million, up from $7.4 million a year earlier.
Analysts surveyed by FactSet expected $14 million.
The company said it had cash, cash equivalents and marketable securities of $1.22 billion as of March 31 to finance its expected operating expenses and capital expenditure requirements into 2028.
Price: 18.75, Change: -1.07, Percent Change: -5.40
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。